Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes

Conclusions: The results of this study are consistent with the hypothesis that the use of GLP-1 receptor agonists and DPP-4 inhibitors, separately, may decrease the risk of prostate cancer when compared with the use of sulfonylureas.
Source: Epidemiology - Category: Epidemiology Tags: Pharmacoepidemiology Source Type: research